This CPB has been revised to state that cerliponase alpha (Brineura) is considered medically necessary for children 3 years of age or older who meet the following criteria: 1) the member has a documented diagnosis of symptomatic late infantile neuronal ceroid lipofuscinosis type 2 (CLN2); 2) the diagnosis of CLN2 was confirmed by TPP1 deficiency or the detection of pathogenic mutations in each allele of the TPP1 gene; and 3) the member does not have acute intraventricular access device-related complications or a ventriculoperitoneal shunt. This CPB is revised to state that continued use of cerliponase alpha is considered medically necessary when the following criteria are met: 1) there is documentation indicating that cerliponase alfa use has slowed the loss of ambulation from baseline; and 2) the member does not have acute intraventricular access device-related complications or ventriculoperitoneal shunts.